Research & Education at Mayo Ayalew Tefferi, M.D., a professor of medicine and a consultant in hematology at Mayo Clinic Rochester. He has received several honors and awards for his teaching and research excellence, including the William Summerskill Award, the Dean's Recognition Award, and the Teacher of the Year Hall of Fame.
Ayalew Tefferi's 972 research works Biography. Dr Ayalew Tefferi was born in Addis Ababa, Ethiopia, and migrated to the United States in after completing his medical school education at the University of Athens in Athens, Greece.
Dr. Tefferi has devoted his Dr Ayalew Tefferi was born in Addis Ababa, Ethiopia, and migrated to the United States in after completing his medical school education at the University of Athens in Athens, Greece.
Ayalew Tefferi is a hematologist Dr. Ayalew Tefferi is a hematologist in Rochester, Minnesota and is affiliated with Mayo Clinic-Rochester. He received his medical degree from University of Athens and has been in practice for.
Chronic neutrophilic leukemia (CNL) Ayalew Tefferi, MD Dr. Tefferi, Associate Editor for Mayo Clinic Proceedings since , has been on the Editorial Board since He has been a professor in Hematology and Internal Medicine at Mayo Clinic since
Ayalew Tefferi MD 23. Dr. Ayalew Tefferi, MD is a hematologist in Rochester, MN. He is accepting new patients and telehealth appointments. Areas of Expertise • Dr. Tefferi specializes in the areas of Hematology & Internal Medicine. See board certifications. Explains Conditions Well • Patients said this doctor explains conditions well. See reviews.
Ayalew Tefferi, MD. Mayo Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective year rates of 26%, 16%, and 4%. Current treatment strategies in .
Objective: To document the
Disease overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus and risk of leukemic or fibrotic transformation.